Helicobacter pylori infection rate in patients treated with rifampicin - Eradication effect of rifampicin on Helicobacter pylori

S. Fujimura, T. Kawamura, N. Asou, H. Takahashi, A. Watanabe

    研究成果: Article査読

    2 被引用数 (Scopus)

    抄録

    Eradication therapy of Helicobacter pylori infection by standard proton pump inhibitor-based triple therapies (clarithromycin and amoxicillin) has been correlated with cure of peptic ulcer disease. On the other hand an increase in drug-resistant H. pylori has been reported to be a clinical problem. Thus, the aim of this study was to clarify the effect of rifampicin by susceptibility tests and in vitro inducement of drug resistance on H. pylori. In the in vivo study, anti-H. pylori IgG antibody and the [13C] urea breath test were used in a total 40 tuberculosis and atypical tuberculosis patients treated with rifampicin. The prevalence of H. pylori infection was low in the patients treated with rifampicin, and the eradication rate was 23.1%. The results of this study suggested that rifampicin eradicates H. pylori in tuberculosis and atypical tuberculosis patients treated with the drug.

    本文言語English
    ページ(範囲)839-842
    ページ数4
    ジャーナルJapanese Journal of Chemotherapy
    48
    11
    出版ステータスPublished - 2000 1月 1

    ASJC Scopus subject areas

    • 薬理学
    • 薬理学(医学)

    フィンガープリント

    「Helicobacter pylori infection rate in patients treated with rifampicin - Eradication effect of rifampicin on Helicobacter pylori」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

    引用スタイル